The Association of Interleukin‐36 Staining Intensity and Response to Biologic Therapy in Patients With Psoriasis: A Retrospective Immunohistochemical and Chart Review Pilot Study
- 8 October 2024
- journal article
- research article
- Published by Wiley in Journal of Cutaneous Pathology
- Vol. 52 (1) , 48-53
Abstract
Background: There are limited surrogate biomarkers to identify the active inflammatory pathway in psoriasis to direct treatment with targeted biologic therapies. We investigated the association of interleukin (IL)‐36 epidermal expression, a diagnostic marker of psoriasis, with response to biologic therapy in patients with psoriasis.Methods: Retrospective immunohistochemical and chart review pilot study.Results: Patients with psoriasis with low (scores 0–2) vs. high (scores 3–4) IL‐36 expression did not have significantly different response rates to tumor necrosis factor α (TNFα), IL‐17, and IL‐12/23 or IL‐23 inhibitors; and similarly, mean IL‐36 expression scores did not significantly differ among responders vs. non‐responders to each treatment mechanism. However, in patients with psoriasis treated with IL‐12/23 or IL‐23 inhibitors, there was a marked absolute difference in response rates in those with high vs. low IL‐36 (84% vs. 50%, p = 0.12) and in mean IL‐36 scores in responders vs. non‐responders (3.35 vs. 2.57, p = 0.19).Conclusions: Patients with psoriasis with high IL‐36 expression were more likely to respond to IL‐12/23 and IL‐23 inhibition than those with low IL‐36, though these findings were not statistically significant. Additional studies with larger sample sizes are needed to validate and expand upon these findings.Keywords
This publication has 21 references indexed in Scilit:
- Role of IL-36 cytokines in psoriasis and other inflammatory skin conditionsCytokine, 2022
- IL-36 and IL-17A Cooperatively Induce a Psoriasis-Like Gene Expression Response in Human KeratinocytesJournal of Investigative Dermatology, 2021
- Pathophysiology, Clinical Presentation, and Treatment of PsoriasisJAMA, 2020
- Comparison of Biologics and Oral Treatments for Plaque PsoriasisJAMA Dermatology, 2020
- Clinicopathologic overlap of psoriasis, eczema, and psoriasiform dermatoses: A retrospective study of T helper type 2 and 17 subsets, interleukin 36, and β-defensin 2 in spongiotic psoriasiform dermatitis, sebopsoriasis, and tumor necrosis factor α inhibitor–associated dermatitisJournal of the American Academy of Dermatology, 2020
- IL-36γ (IL-1F9) Is a Biomarker for Psoriasis Skin LesionsJournal of Investigative Dermatology, 2015
- Comparative Genomic Profiling of Synovium Versus Skin Lesions in Psoriatic ArthritisArthritis & Rheumatology, 2014
- IL-36 in psoriasisCurrent Opinion in Pharmacology, 2012
- Inter-Regulation of Th17 Cytokines and the IL-36 Cytokines In Vitro and In Vivo: Implications in Psoriasis PathogenesisJournal of Investigative Dermatology, 2011
- PsoriasisNew England Journal of Medicine, 2009